Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dexlansoprazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A known ✓ | P20648 | 4/20 | 0.61 |
| ▸ | ATP4B known ✓ | P51164 | 4/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.63 |
| ▸ | NPC1 | O15118 | 3/20 | 0.63 |
| ▸ | RAB9A | P51151 | 3/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | WDR5 | P61964 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | ENGASE | Q8NFI3 | 3/20 | 0.61 |
| ▸ | SARM1 | Q6SZW1 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | ATP1A1 | P05023 | 3/20 | 0.61 |
| ▸ | ATP1B1 | P05026 | 3/20 | 0.61 |
| ▸ | ATP1A3 | P13637 | 3/20 | 0.61 |
| ▸ | ATP1B2 | P14415 | 3/20 | 0.61 |
| ▸ | ATP1A2 | P50993 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexlansoprazole SCHEMBL29950208 | 1.00 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Dexlansoprazole SCHEMBL29598842 | 1.00 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL29353345 | 1.00 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Dexlansoprazole SCHEMBL29750802 | 1.00 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL8597994 | 1.00 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL1559598 | 1.00 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL29358567 | 1.00 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Dexlansoprazole SCHEMBL44975 | 1.00 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL22366 | 1.00 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL22365 | 1.00 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1453 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090593-A2 | RNA BIOMARKERS FOR USE IN BARRETT'S ESOPHAGUS | CITY OF HOPE (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4731180-A1 | A POWDER COMPOSITION FOR ORAL SUSPENSION OF PROTON PUMP INHIBITORS AND THE METHOD OF PREPARING THE SAME | Orbit Pharma Limited (GB) | 2026-04-29 | — | — | EP | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-20260091116-A1 | COMPOSITIONS AND KITS FOR OMEPRAZOLE SUSPENSION | AZURITY PHARMACEUTICALS, INC. | 2026-04-02 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| US-20260069593-A1 | METHODS FOR TREATING CANCER | AMGEN INC (US) | 2026-03-12 | — | — | US | claimed |
| CN-121570437-A | Dexlansoprazole medicine composition and preparation method thereof | 江苏中邦制药有限公司 | 2026-02-27 | — | — | CN | claimed |
| US-12544376-B2 | Amorphous solid dispersions of dasatinib and uses thereof | HANDA THERAPEUTICS, LLC (US) | 2026-02-10 | — | — | US | claimed |
| EP-3503904-B1 | ASCAROSIDE TREATMENT OF EOSINOPHILIC ESOPHAGITIS | CALIFORNIA INST OF TECHN (US) | 2026-01-21 | — | — | EP | claimed |
| EP-4680203-A1 | COMPOSITIONS FOR SUSTAINED RELEASE OF POORLY SOLUBLE ACTIVE INGREDIENTS | Prolevi Bio AB (SE) | 2026-01-21 | — | — | EP | claimed |
| EP-3986463-A1 | A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS | Hangzhou Dac Biotech Co., Ltd. (CN) | 2022-04-27 | — | — | EP | claimed |
| EP-3986476-A1 | A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE | Hangzhou Dac Biotech Co., Ltd. (CN) | 2022-04-27 | — | — | EP | claimed |
| WO-2022078524-A2 | SPECIFIC CONJUGATION OF AN ANTIBODY | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2022-04-21 | — | — | WO | claimed |
| US-20220096479-A1 | AMORPHOUS SOLID DISPERSIONS OF DASATINIB AND USES THEREOF | HANDA THERAPEUTICS, LLC | 2022-03-31 | — | — | US | claimed |
| WO-2022056103-A1 | METHODS OF PROPHYLAXIS OF CORONAVIRUS INFECTION AND TREATMENT OF CORONAVIRUSES | CUREMARK, LLC (US) | 2022-03-17 | — | — | WO | claimed |
| EP-3965735-A1 | PHARMACEUTICAL FORMULATION | Alkaloid AD Skopje (MK) | 2022-03-16 | — | — | EP | claimed |
| CN-110873767-B | Rapid detection method for dexlansoprazole synthetic intermediate and related substances thereof | 天津药物研究院有限公司 | 2022-03-11 | — | — | CN | claimed |
| WO-2022051503-A1 | METHODS OF ADMINISTERING GLUTAMINASE INHIBITORS | CALITHERA BIOSCIENCES, INC. (US) | 2022-03-10 | — | — | WO | claimed |
| US-11260030-B2 | Oral tablet for delivery of active ingredients to the gastrointestinal tract | FERTIN PHARMA A/S (DK) | 2022-03-01 | — | — | US | claimed |
| CN-114040781-A | Formulation of conjugate of TUBULYSIN derivative and cell binding molecule | 杭州多禧生物科技有限公司 | 2022-02-11 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069593-A1 | METHODS FOR TREATING CANCER | KRAS, NRAS, HRAS | ATP4A 605/4885ATP4B 466/4885CYP2C9 2502/4885 |
| US-20260091116-A1 | COMPOSITIONS AND KITS FOR OMEPRAZOLE SUSPENSION | MLN, MUC1, CFD | ATP4A 522/4885ATP4B 363/4885CYP2C9 244/4885 |
| US-12544376-B2 | Amorphous solid dispersions of dasatinib and uses thereof | ABL1, SRC, ABL2 | ATP4A 672/4885ATP4B 696/4885CYP2C9 655/4885 |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | CD4, TAP1, MCTS1 | ATP4A 1935/4885ATP4B 3159/4885CYP2C9 4852/4885 |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | DCLRE1A, CCR3, CCR8 | ATP4A 3687/4885ATP4B 4614/4885CYP2C9 3299/4885 |
| US-20220096479-A1 | AMORPHOUS SOLID DISPERSIONS OF DASATINIB AND USES THEREOF | NRAS, ABL2, APC | ATP4A 879/4885ATP4B 1003/4885CYP2C9 3044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.